Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 20/20 | 0.89 |
| ▸ | GNA15 | P30679 | 1/20 | 0.76 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.76 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.76 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.76 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15125767 | 1.00 | FFAR1 (0.89) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL3450662 | 0.94 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL1632685 | 0.94 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL15125897 | 0.94 | FFAR1 (0.79) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL1633142 | 0.94 | FFAR1 (1.00) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16690557 | 0.93 | FFAR1 (0.91) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16684725 | 0.93 | FFAR1 (0.86) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16123744 | 0.91 | FFAR1 (0.74) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL15125747 | 0.91 | FFAR1 (0.74) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL16347645 | 0.89 | FFAR1 (0.78) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9139548-B2 | Polycyclic derivatives, preparation process and pharmaceutical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-09-22 | — | — | US | disclosed |
| US-20150005282-A1 | POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2015-01-01 | — | — | US | disclosed |
| EP-2803664-A1 | POLYCYCLIC DERIVATIVES, PREPARATION METHOD AND MEDICAL USES THEREOF | Jiangsu Hengrui Medicine Co. Ltd. (CN) | 2014-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005282-A1 | POLYCYCLIC DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF | GPR119, GPR55, GPR65 | FFAR1 19/4885GNA15 532/4885SLC10A1 437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.